
    
      The primary objective of this study is to determine the objective response rate Complete
      Response + Partial Response(CR+PR) associated with neoadjuvant pazopanib at 8 weeks as
      defined via Response Evaluation Criteria in Solid Tumors (RECIST1.1). The investigators will
      also estimate the recurrence free survival (RFS), specifically the 1 and 2 year rates, with
      recurrence defined via RECIST1.1, and characterize the safety issues. Finally, this study
      also includes a number of exploratory analyses designed to evaluate potential correlations
      between RFS and; serum levels of cytokine and angiogenesis factor (CAF).
    
  